Please login to the form below
The inescapable rise of patient-centricity
The April issue of PME questions the meaning of ‘patient-centricity’ and whether we are achieving it.
Patient-centricity has become a ubiquitous value within the pharmaceutical industry; however, is pharma delivering on its promise to put patients at the heart of everything they do? Dennis O’Brien, Lucid CEO, believes we are making progress but still have a long way to go.
How do we achieve patient-centricity? Dennis believes we must not lose sight of patients. With the evolution of personalised medicine, we must also personalise the value that we deliver to patients. Dennis thinks that technology is the answer. “Tech provides the opportunity to analyse what patients look at on the internet, indicating their values.” However, this is only a starting point. “We’ve got to think like tech providers and think like consumers. If we can do that, we’ll build trusted communities that provide meaningful value. But we’re just not there yet. For some reason we’re scared to connect to patients. We need to get over it.”
Dennis thinks that achieving this requires a fundamental shift in mindset, moving the goal from outcomes to improving someone’s every-day life. “Patient-centricity is a relentless pursuit. The best players in this space will be those who understand that patient insight gives them a continual point of differentiation – and can track, analyse and respond to it quickly to deliver better value to patients.”
Read more about what Dennis and other industry thought leaders have to say on the inescapable rise of patient-centricity here.
Company Details
Lucid Group Communications Limited
Address:
First Floor, Jubilee House
Third Avenue
Globe Park
Marlow
Bucks
SL7 1EY
UK
Latest content on this profile
- My Lucid journey from PMW to Head of Medical
- Working in Medical Communications has never been about the nine to five. Fusing science and language in the service of both clients and patients, this is typically a fast paced and demanding industry, but one which offers enviable flexibility, variety and intellectual challenge. Leading agency Lucid Group prides itself on the many growth and development opportunities it offers its people. In this article, Katherine Duxbury, Lucid’s Head of Medical, reflects upon her own bespoke working journey over the past 12 years and explains how creativity, collaboration and a passion for science have led to a rewarding, stimulating and self-curated career.
Lucid Group Communications Limited
- Listen, learn and lift off
Lucid Group Communications Limited
- Launch excellence
Lucid Group Communications Limited
- Meet The Lucid Group Talent Team
- Meet our talent team, they're here to help and transform your career.We have some exciting roles at all levels in account management and medical writing.If you choose to take your career to the next level with us, you can be assured that you'll have a whole group of people here cheering you on.So, if you’re feeling stuck or unfulfilled in your current role and looking for a company that will provide the personal and career development you need, please check out our open roles here: https://bit.ly/3jhlhUNOr contact one of our talent acquisition managers for a chat:Ellen Field Assoc CIPDElaine DowneyJon TurnerDaniel Newbury
Lucid Group Communications Limited
- Extraordinary lives: advancing change in rare diseases (Part 2)
Lucid Group Communications Limited
- Extraordinary lives: advancing change in rare diseases (Part 2)
- In support of Rare Disease Day, we're excited to launch part 2 of our video series; Extraordinary lives: advancing change in rare diseases.Why is raising awareness of rare diseases so important?Because 300 million people worldwide are living with a rare disease. This means that, collectively, the number of people living with a rare disease is equivalent to the population of the world's third-largest country (USA).While we have come a long way since the inception of Rare Disease Day, there's still plenty of work to do.Part 2 of this series focuses on important topics including the role of technology and the opportunities it presents for the rare disease community. The panel also hold captivating insights on how the pandemic has impacted the use of related digital technologies, the role of gene therapy, the major challenges and successes for pharma companies in supporting the rare disease community over the last 13 years, and much, much more.If you’d like to know more about the work we do in rare diseases or would like advice on any healthcare communication challenges please get in touch with Clare Reynolds on LinkedIn or by email: clare.reynolds@wearelucidgroup.comAbout Lucid GroupFounded in 2007, Lucid Group is a global multi-capability healthcare consultancy with core expertise in medical strategy, healthcare communications, creative and brand strategy, motion, digital and technology, behaviour change, metrics, and data analytics. We partner with the pharma and biotech industry, delivering life-transforming value with connected capabilities to create pioneering solutions that change behaviour, improve clinical practice and advance health outcomes. Transforming lives. Always.
Lucid Group Communications Limited
